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INTRODUCTION
Amyloidoses are protein conformation disorders, in which
different soluble proteins aggregate as extracellular
insoluble fibrils.1 Amyloid fibrils associate with other
moieties, including glycosaminoglycans and serum
amyloid P component (SAP), forming deposits that
disrupt the structure and function of tissues and organs.2
Systemic amyloidoses are subdivided into familial
amyloidosis (AF), secondary amyloidosis (AA) in
patients with long-standing infections or inflammatory
processes, senile amyloidosis (wild-type ATTR), and
immunoglobulin light-chain amyloidosis (AL).3 Primary
amyloidosis (AL) represents the most common form of
systemic amyloid deposition and is typically associated
with immunocyte dyscrasias such as multiple myeloma,
lymphomas, macroglobulinemia and “benign” monoclonal
gammopathies.4
Secondary systemic AA amyloidosis can complicate
chronic inflammatory disorders that are associated with
a sustained acute-phase response. AA amyloid fibrils
are derived from the acute-phase reactant serum
amyloid A (SAA) protein.1 Associated disorders include
adult rheumatoid arthritis, juvenile rheumatoid arthritis,
ankylosing spondylitis, Reiter's syndrome, systemic
lupus erythematosus, systemic sclerosis, tuberculosis,
leprosy, Castleman's disease, bronchiectasis, cystic
fibrosis, osteomyelitis, heroin abuse, psoriasis, inflam-
matory bowel disease and Whipple's disease.4
Previously, there have been reports on association of
cholestasis and amyloidosis, but literature does not
report an association of secondary amyloidosis and
biopsy proven primary billiary cirrhosis from Pakistan.
We report here a case of secondary amyloidosis with
primary billiary cirrhosis (antimitochondrial antibody
negative) along with extensive gastrointestinal and renal
involvement.
CASE REPORT
A 49 years old lady presented with low-grade fever (99-
100°F) for 2 years. During this time she was extensively
worked-up for pyrexia of unknown origin but no
diagnosis could be established. Her initial blood workup
was all negative except high alkaline phosphatase
and gamma GT (374 IU and 195 IU respectively).
Hepatitis serology, bone marrow, CSF, CT chest; all
were normal. CT abdomen showed poorly defined
hypodense lesions in right lobe of liver (segment VI
and VII), no splenomegaly and no lymphadenopathy.
Autoimmune workup (ANA, Anti DNA, ASMA, AMA
ANCA) all were negative. CA 125, AFP, CEA and CA 15-
3 were all negative.
She later presented to our tertiary care centre with facial
swelling, flushing and bilateral pedal swelling for 3
months. Along with generalized body swelling, she had
frothy urine. She was diagnosed as nephrotic syndrome
on the basis of nephrotic range proteinuria and was
started on steroids prior to presentation at our centre.
Her fever had subsided in a week after starting steroids.
She had a past history of hypertension and had
undergone hysterectomy. Her appetite was decreased
and she had loose motions occasionally. She was
currently on prednisolone, spironolactone, furosemide
and simvastatin.
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On examination, she was a middle aged lady well
preserved. She had blood pressure of 101/68 mmHg.
She was afebrile, with respiratory rate of 22
breaths/minute, pulse of 90 beats/minute. She was pale,
had puffy face and had ankle oedema. Cardiovascular
examination was unremarkable. Chest had decreased
air entry at bases. Abdomen was distended with
abdominal striae and liver was palpable. Initial
laboratory investigations are shown in Table I.
The initial differential diagnosis on admission was
Iatrogenic Cushing syndrome, nephrotic syndrome and
cholestatic liver. Along with this, the lady had history of
pyrexia of unknown origin (PUO) which was the primary
disease responsible for the current presentation. The
differential diagnosis of PUO at this point was
malignancy (solid tumour), lymphoma (which resolved
with steroids), autoimmune disease or tuberculosis.
The repeat CT chest and abdomen showed portal
vein thrombosis, wedge shaped areas in liver and
chronic liver parenchymal disease. Further, laboratory
investigations sent during the admission are shown in
Table I. Renal biopsy was done which was suggestive
of amyloidosis (Figure 1). It was positive for AA amyloid.
The dilemma still in this patient, was the cause of
secondary amyloidosis. Her workup so far was
inconclusive (no malignancy, autoimmmune workup
was negative, no evidence of chronic infection). During
this time she again developed increased frequency of
loose stools. Stool DR did not show any pus cells. Upper
GI endoscopy and colonoscopy were performed. Biopsy
of body and antrum of stomach showed non-specific
gastritis, duodenum terminal iluem and caecum showed
amyloidosis and descending colon showed moderate
focal active colitis. At this point the liver biopsy slides
(which were done earlier) were reviewed after carrying
out special stains with trichrome and cytokeratin which
were not done earlier (Figure 2). The liver biopsy
revealed dense acute and chronic portal inflammation
(lymphocyte, plasma cell and occasional neutrophils)
with interface hepatitis with lobular activity, feathery
degeneration of hepatocytes, cholestatic liver cell
rossettes and paucity of bile ducts. It was negative for
amyloid.
Hence, the final diagnosis was 49 years old female with
primary biliary cirrhosis (antimitochondrial antibody
negative) leading to secondary amyloidosis. She was
treated with ursofac for PBC along with diuretics and
ACE inhibitors and anticoagulation.
DISCUSSION
Hepatic involvement in amyloidosis has been reported
previously. Associations have been found with primary
biliary cirrhosis and cholestasis from Northern America.5
We report a case of PBC (AMA negative), leading to
amyloidosis with extensive gastrointestinal and renal
Table I: Initial laboratory investigations.
Workup on initial presentation
Hb: 13.2 g/dl T bil: 0.4 mg/dl
WBC: 15.6  X 10E9/L (63% N) SGPT: 42 IU/L
Plt: 215 X 10E9/L AP: 599 IU/L
BUN: 8 mg/dl Gamma GT:374 IU/L
Cr: 0.7 mg/dl T prot: 3.8 g/dl
Na: 133 mg/dl LDH: 812 IU/L
K: 2.9 mg/dl UA: 4.3 mg/dl
Cl: 108 mg/dl PT/APTT : Normal
HCO: 21.6 mg/dl Urine DR: +3 protien
RBS: 108 mg/dl
Workup during admission
Serum protein Electrophoresis: normal Autoimmune workup
ESR: 56 mm ANA
Hepatitis B sAg: -ve Anti DNA
Hepatitis C Ab: -ve ASMA -ve
24 Urinary protein: 5.3 gm/day AMA
Calcium: 7.2 mg/dl LKM
CRP: 3.8 mg/dl Tumour markers
Cortisol: 9.80 µg/dl CEA: 7.41 ng/ml
Hypercoaguable workup: -ve Alpha feto protein: 6 IU/ml 
Bone marrow : Normal
Figure 1: Renal biopsy showing amyloid deposits.
Figure 2: Liver biopsy with cytokeratin and trichrome stain cytokeratin.
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involvement. The typical PBC diagnostic criteria includes
(i) ALP levels at least twice or γ-glutamyl transpeptidase
(γGT) levels at least five times the upper limit of normal,
(ii) positive AMA, and (iii) a liver biopsy showing florid
bile duct lesion.6 However, AMA negative PBC patients
appear to have a disease that otherwise is identical to
the AMA positive cases.7 A liver biopsy is necessary for
the diagnosis of PBC to be established in the absence of
AMA.8 This patient had AMA negative PBC based on the
clinical history of pruritis, high alkaline phosphatase,
gamma glutamine transferase and histological finding of
PBC (degenerating bile duct epithelium with focal bile
duct obliteration, severe lymphocytic interface hepatitis,
portal lymphocytic infiltrate).9
Previous cases have been reported on PBC leading to
amyloidosis, however, this was mainly AMA positive
PBC.5 Clinically patients with PBC with amyloidosis
presents as end stage liver disease manifesting as
ascites, encephalopathy, and recurrent oesophageal
variceal bleeding.5 Rodriguez-luna reports a case of
primary biliary cirrhosis and systemic amyloidosis in
which the patient presented with symptoms (ascites,
encephalopathy, recurrent variceal bleeding) of end
stage liver disease. This patient was referred for liver
transplant, before that a renal biopsy was done to
identify the cause of the renal dysfunction which showed
amyloidosis. Subsequently, liver biopsy also revealed
amyloidosis.5 However, the patient did not present as
decompensated cirrhosis, rather only, with symptoms of
cholestasis along that gastrointestinal involvement
secondary to amyloidosis. The liver biopsy did not show
any evidence of amyloidosis, hence this patient had
secondary amyloidosis. Jeong reported 2 similar cases
who presented with hepatic encephalopathy and on liver
biopsy were found to have amyloidosis.10 Peter reported
5 cases of primary amyloidosis and severe intrahepatic
cholestatic jaundice, but amyloid deposits were present
on liver biopsy of most of these patients.11
Secondary amyloidosis (AA) is associated with long-
standing infectious or non-infectious inflammatory
disorders and, less frequently, neoplastic disorders.4
There are case reports on association of primary billiary
cirrhosis and cutaneous amyloidosis.12 However, after
extensive literature search we could not find any case
of AMA negative PBC associated with secondary
amyloidosis. The prognosis of secondary amyloidosis is
dependent on the treatment of the primary disease or
inflammatory state. The timely recognition of AMA
negative PBC is not only important from a classification
standpoint, but it may have implications for therapy.
UDCA has been demonstrated in randomized, controlled
trials to be an effective therapy for the treatment of PBC.
In summary, amyloidosis is a disease which is usually
diagnosed late in its course due to its variable clinical
presentation. Moreover, prognosis of secondary amyloi-
dosis is dependant on the primary disease. Primary
biliary cirrhosis (AMA negative) as a primary cause is
often difficult to diagnose and hence treatment is
delayed leading to a complicated course of amyloidosis
in such cases.
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